Obliterative Bronchiolitis

Lung and Heart–Lung Transplantation

Volumn , Issue , 2006, Pages 723-751

  Verleden, Geert M ^a   Dupont, Lieven J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58849100575     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420019285-35     Document Type: Chapter

References (155)

1. Trulock EP, Edwards LB, Taylor DO, et al. The registry of the international society for heart and lung transplantation: twenty-first official adult heart–lung report—2004. J Heart Lung Transplant 2004; 23:804–815.
2. Vricella LA, Karamichalis JM, Ahmad S, et al. Lung and heart–lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience. Ann Thorac Surg 2002; 74:13–18.
3. Cassivi SD, Meyers BF, Battafarano RJ, et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002; 74:1663–1670.
4. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12:713–716.
5. Reichenspurner H, Girgis RE, Robbins BC, et al. Stanford experience with obliterative bronchiolitis after lung and heart–lung transplantation. Ann Thorac Surg 1996; 62:1547–1573.
6. Meyers BF, Lynch J, Trulock EP, et al. Lung transplantation: a decade of experience. Ann Surg 1999; 230:362–370.
7. Whitehead B, Rees P, Sorensen K, et al. Incidence of obliterative bronchiolitis after heart–lung transplantation in children. J Heart Lung Transplant 1993; 12:903–908.
8. Tamm M, Sharples L, Higenbottam T, et al. Bronchiolitis obliterans syndrome (BOS) following heart–lung transplantation. Transpl Int 1996; 9(Suppl 1): S299–S302.
9. Glanville AR, Baldwin JC, Burke CM, et al. Obliterative bronchiolitis after heart–lung transplantation: apparent arrest by augmented immunosuppression. Ann Int Med 1987; 107:300–304.
10. Loubeyre P, Reven D, Delignette A, et al. Bronchiectasis detected with thin section CT as a predictor of chronic lung allograft rejection. Radiology 1995; 194:213–216.
11. Verleden GM. Bronchiolitis obliterans syndrome after lung transplantation: medical treatment. Monaldi Arch Chest Dis 2000; 55:140–145.
12. Verleden GM, Bankier A, Boehler A, et al. Bronchiolitis obliterans syndrome after lung transplantation: diagnosis and treatment. Eur Respir Monogr 2005; 29:19–43.
13. Jackson CH, Sharples LD, McNeil K, et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant 2002; 21:658–666.
14. Van den Berg JW, Geertsma A, van der Bij W, et al. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med 2000; 161:1937–1941.
15. Vermeulen KM, Groen H, van der Bij W, et al. The effect of bronchiolitis obliterans syndrome on health related quality of life. Clin Transplant 2004; 18:377–383.
16. Van den Berg JW, van Enckevort PJ, TenVergert EM, et al. Bronchiolitis obliterans syndrome and additional costs of lung transplantation. Chest 2000; 118:1648–1652.
17. Yousem SA, Berry GH, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1–15.
18. Verleden GM, Dupont J, Van Raemdonck D. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J 2005; 25:221–224.
19. Yousem SA, Paradis I, Griffith BP. Can transbronchial biopsy aid in the diagnosis of bronchiolitis obliterans in lung transplant recipients? Transplantation 1994; 57:151–152.
20. Sibley RK, Berry GJ, Tazelaar HD, et al. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 1993; 12:308–324.
21. Estenne M, Maurer J, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297–310.
22. Stewart S. The pathology of lung transplantation. Semin Diagn Pathol 1992; 9:210–219.
23. Yousem SA. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am J Surg Pathol 1993; 17:491–496.
24. Ross DJ, Marchevsky A, Kramer M, et al. ‘‘Refractoriness’’ of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant 1997; 16:832–838.
25. Verbeken EK, Stewart S. Bronchiolitis obliterans syndrome and bronchiolitis obliterans in lung transplantation: will a pathologist and a physician ever meet? Eur Respir Monogr 2004; 29:55–65.
26. Palmer SM, Miralles AP, Howell DN, et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000; 118:1214–1217.
27. Sharples LD, Mc Neil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21:271–281.
28. Kroshus TJ, Kshettry VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114:195–202.
29. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart–lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110:4–13.
30. Stanbrook MB, Kesten S. Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans. Am J Respir Crit Care Med 1999; 160:2034–2039.
31. Kshettry VR, Kroshus TJ, Savik K, et al. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 1996; 110:704–709.
32. Ward CW, De Soyza T, Keating DT, et al. Infection and bronchiolitis obliterans syndrome in lung transplant recipients. Eur Respir Monogr 2004; 29:44–54.
33. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170:1022–1026.
34. Egan JJ. Obliterative bronchiolitis after lung transplantation. A repetitive multiple injury airway disease. Am J Respir Crit Care Med 2004; 170: 931–932.
35. Husain AN, Siddique MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159:829–633.
36. Heng D, Sharples L, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17:1255–1263.
37. Quantz MA, Bennett LE, Meyer DM, et al. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000; 19:473–479.
38. Schulman LL, Weinberg AD, McGregor C, et al. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157:1833–1837.
39. van den Berg JW, Hepkema BG, Geertsma A, et al. Long-term outcome of lung transplantation is predicted by the number of HLA-DR mismatches. Transplantation 2001; 71:368–373.
40. Hadjiliadis D, Davis RD, Palmer SM. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients? Chest 2002; 122:1168–1175.
41. Tamm M, Aboyoun CL, Chajet PN, et al. Treated Cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170:1120–1123.
42. Billings JL, Hertz MI, Savik K. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21:559–566.
43. Garbino J, Gerbase MW, Wunderli W, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004; 125:1033–1039.
44. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk factor for bronchiolitis obliterans syndrome and death. Am J Respir0Crit Care Med 2004; 170:181–187.
45. Gerhardt S, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2003; 168:121–125.
46. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77:1465–1467.
47. Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25:490–493.
48. Baudet EM, Dromer C, Dubrez J, et al. Intermediate term results after en-bloc double-lung transplantation with bronchial arterial revascularization. J Thorac Cardiovasc Surg 1996; 112:1292–1299.
49. Yacoub M, Al-Kttan KM, Tadjkarimi S, et al. Medium term results of direct bronchial revascularization using IMA for single lung transplantation (SLT) with direct revascularization. Eur J Cardiothor Surg 1997; 11:1030–1036.
50. Norgaard M, Andersen C, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation? Eur J Cardiothorac Surg 1998; 14:311–317.
51. Nowak K, Kamler M, Bock M, et al. Bronchial artery revasculariazation affects graft recovery after lung transplantation. Am J Respir Crit Care Med 2002; 165:216–220.
52. Palmer SM, Miralles AP, Howell DN, et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000; 118:1214–1217.
53. Young LR, Hadjiliadis D, Davis D, et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124:1689–1693.
54. Cantu E III, Appel JZ III, Hartwig MG, et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78:1142–1151.
55. Davis D, Lau CL, Eubanks SS, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125:533–542.
56. Maes BD, Vanwalleghem J, Kuypers D, et al. Differences in gastric motor activity in renal transplant patients treated with FK-506 versus ciclosporine. Transplantation 1999; 68:1482–1485.
57. Verleden GM, Besse T, Maes B. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. Transplantation 2002; 73:1974–1976.
58. Hartwig MG, Cantu E, Appel JZ, et al. Non-alloimmune injury mediated by gastroesophageal reflux precipitates alloimmune injury in lung transplant patients. J Heart Lung Transplant 2004; 23:S43.
59. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15:1200–1208.
60. Hosenpud JD, Bennett LE, Keck BM, et al. The registry of the International Society of Heart and Lung Transplantation: Seventeenth Official Report— 2000. J Heart Lung Transplant 2000; 19:909–931.
61. Ciccone AM, Stewart KC, Meyers BF, et al. Does donor cause of death affect the outcome of lung transplantation? J Thorac Cardiovasc Surg 2002; 123:429–434.
62. Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73:1041–1047.
63. Fisher AJ, Wardle J, Dark JH, et al. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002; 21:1206–1212.
64. Pomerance A, Madden B, Burke MM, et al. Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. J Heart Lung Transplant 1995; 14:761–763.
65. Kramer MR, Stoehr C, Wang JL, et al. The diagnosis of obliterative bronchiolitis after heart–lung and lung transplantation: low yield of transbronchial biopsies. J Heart Lung Transplant 1993; 12:675–681.
66. Patterson GM, Wilson S, Whang JL, et al. Physiologic definitions of obliterative bronchiolitis in heart–lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second. J Heart Lung Transplant 1996; 15:175–181.
67. Reynaud-Gaubert M, Thomas P, Badier M, et al. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage findings. Am J Respir Crit Care Med 2000; 161(6):1924–1929.
68. Ouwens JP, van der Mark TW, Koeter GH, et al. Bronchiolar airflow impairment after lung transplantation: an early and common manifestation. J Heart Lung Transplant 2002; 21:1056–1061.
69. Hachem RR, Chakinala MM, Yusen RD, et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med 2004; 169:468–472.
70. Ikonen T, Kivisaari L, Taskinen E, et al. High-resolution CT in long-term follow-up after lung transplantation. Chest 1997; 111:370–376.
71. Worthy SA, Park CS, Kim JS, et al. Bronchiolitis obliterans after lung transplantation: high-resolution CT findings in 15 patients. AJR Am J Roentgenol 1997; 169:673–677.
72. Leung AN, Fisher K, Valentine V, et al. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest 1998; 113:365–370.
73. Bankier AA, Van Muylem A, Knoop C, et al. Bronchiolitis obliterans syndrome in heart–lung transplant recipients: diagnosis with expiratory CT. Radiology 2001; 218:533–539.
74. Knollmann FD, Ewert R, Wundrich T, et al. Bronchiolitis obliterans syndrome in lung transplant recipients: use of spirometrically gated CT. Radiology 2002; 225:655–662.
75. Lee E-S, Gotway MB, Reddy GP, et al. Early bronchiolitis obliterans following lung transplantation. Radiology 2000; 216:472–477.
76. Millet WT Jr, Kotlof RM, Blumenthal NP, et al. Utility of high resolution computed tomography in predicting bronchiolitis obliterans syndrome following lung transplantation: preliminary findings. J Thorac Imaging 2001; 16:76–80.
77. Estenne M, Van Muylem A, Knoop C, et al. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution. Am J Respir Crit Care Med 2000; 162:1047–1051.
78. Reynaud-Gaubert M, Thomas P, Badier M, et al. Early detection of airway involvement in obliterative bronchioltiis after lung transplantation. Functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med 2000; 161:1924–1929.
79. Arens R, McDonough M, Zhao H, et al. Altered lung mechanics after doublelung transplantation. Am J Respir Crit Care Med 1998; 158:1403–1409.
80. Fisher AJ, Gabbay E, Small T, et al. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax 1998; 53:454–458.
81. Verleden GM, Dupont LJ, Lamont J, et al. Is there a role for measuring exhaled nitric oxide in lung transplant recipients with chronic rejection? J Heart Lung Transplant 1998; 17:231–232.
82. Gabbay E, Walters EH, Orsida B, et al. Post-lung transplant bronchiolitis obliterans syndrome is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med 2000; 162:2182–2187.
83. Verleden GM, Dupont LJ, Delcroix M, et al. Exhaled nitric oxide after lung transplantation: impact of the native lung. Eur Respir J 2003; 21:429–432.
84. Verleden GM, Dupont L, Van Raemdonck D, et al. Accuracy of exhaled nitric oxide measurements for the diagnosis bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 78:730–733.
85. Verleden GM, Dupont J, Van Raemdonck D, et al. The effect of switching cyclosporine A to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant 2003; 22:908–913.
86. Reichenspurner H, Kur F, Treede H, et al. Optimization of an immunosuppressive protocol after lung transplantation. Transplantation 1999; 68:67–71.
87. Ross DJ, Waters PF, Levine M, et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 1998; 17:768–774.
88. Gerbase MW, Spiliopoulos A, Fathi M, et al. Low doses of mycophenolate mofetil with low doses of tacrolimus prevent acute rejection and longterm function loss after lung transplantation. Transplant Proc 2001; 33: 2146–2147.
89. O’Hair DP, Cantu E, McGregor C, et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant 1998; 17:864–868.
90. Palmer SM, Baz MA, Sanders L, et al. Results of a randomised, prospective, multicenter trial of mycophenolate mofetil and azathioprine in the prevention of acute rejection. Transplantation 2001; 71:1772–1776.
91. Corris P, Glanville A, McNeil K, et al. One year analysis of an ungoing international randomized study of mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantion. J Heart Lung Transplant 2001; 20(Suppl): 149–150.
92. Horning N, Lynch J, Sundaresan S, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17:761–767.
93. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18:448–455.
94. Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21:435–439.
95. Sarahrudi K, Carretta A, Wisser W, et al. The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int 2002; 15:24–28.
96. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic allograft rejection. J Thorac Cardiovasc Surg 2004; 127:1126–1132.
97. Zuckermann A, Reichenspurner H, Jaksch P, et al. Long term follow up of a prospective randomised trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. J Heart Lung Transplant 2003; 22(Suppl):S76–S77.
98. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60:580–585.
99. Kur F, Reichenspurner H, Meiser BM, et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. J Thorac Cardiovasc Surg 1999; 47:174–178.
100. Ross DJ, Jordan SC, Nathan SD, et al. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials. Chest 1996; 109:870–873.
101. Reichenspurner H, Robbins R, Miller J, et al. RATG-induction therapy significantly reduces incidence of acute pulmonary rejection compared to OKT3 treatment. J Heart Lung Transplant 1996; 15:S103.
102. Wiebe K, Harringer W, Wahlers T, et al. ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference? Transplant Proc 1998; 30:1517–1518.
103. Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation. Chest 1999; 116:127–133.
104. Garrity ER, Villanueva J, Bhorade SM, et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001; 71:773–777.
105. Sweet SC, De La Morena MT, Shapiro SD, et al. Interleukin-2-receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplant recipients. J Heart Lung Transplant 2001; 20:221–222.
106. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2001; 20:1282–1290.
107. Valantine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart–lung and lung allografts. Chest 1996; 109: 1184–1189.
108. Takao M, Higenbottam TW, Audley T, et al. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart–lung transplant recipients. Transplant Proc 1995; 27:1284–1285.
109. De Soyza A, Fisher AJ, Small T, et al. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med 2001; 164:1209–1212.
110. Andreu G, Achkar A, Couetil JP, et al. Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant 1995; 14:793–796.
111. Cahill BC, O’Rourke MK, Strasburg KA, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15:1130–1137.
112. Soghikian MV, Valentine VG, Berry GJ, et al. Impact of ganciclovir prophylaxis on heart–lung and lung transplant recipients. J Heart Lung Transplant 1996; 15:881–887.
113. Tikkanen JM, Kallio EA, Bruggeman CA, et al. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med 2001; 15:672–679.
114. Ross DJ, Lewis MI, Kramer M, et al. FK 506 rescue immunosuppression for obliterative bronchiolitis after lung transplantation. Chest 1997; 112: 1175–1179.
115. Kesten S, Chaparro C, Scavuzzo M, et al. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant 1997; 16: 905–912.
116. Reichenspurner H, Meiser BM, Kur F, et al. First experience with FK 506 for treatment of chronic pulmonary rejection. Transplant Proc 1995; 27:2009.
117. Knoop C, Antoine M, Vachiery JL, et al. FK 506 rescue therapy for irreversible airway rejection in heart–lung transplant recipients: report on five cases. Transplant Proc 1994; 26:3240–3241.
118. Wiebe K, Harringer W, Franke U, et al. FK506 rescue therapy in lung transplantation. Transplant Proc 1998; 30:1508–1509.
119. Lipson DA, Palevsky HI, Kotloff RM, et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc 1998; 30:1505–1507.
120. Revell MP, Lewis ME, Llewellyn-Jones CG, et al. Conservation of smallairway function by tacrolimus/cycosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000; 19:1219–1223.
121. Whyte RI, Rossi SJ, Mulligan MS, et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 1997; 64:945–948.
122. Speich R, Boehler A, Thurnheer R, et al. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage. Transplantation 1997; 15:533–535.
123. Roman A, Bravo C, Monforte V, et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. Transplant Proc 2002; 34:146–147.
124. Dupont LJ, Delcroix M, Vanhaecke J, et al. Azathioprine/mycophenolate conversion in the management of bronchiolitis obliterans syndrome (BOS) following (heart)–lung transplantation. J Heart Lung Transplant 2003; 22(Suppl):S123.
125. Whitford H, Walters EH, Levvey B, et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 2002; 73:1793–1797.
126. Whitford H, Orsida B, Kotsimbos T, et al. Bronchoalveolar lavage cellular profiles in lung transplantation: the effect of inhaled corticosteroids. Ann Transplant 2000; 5:31–37.
127. Ward C, De Soyza A, Fisher A, et al. Reticular basement membrane thickening in airways of lung transplant recipients is not affected by inhaled corticosteroids. Clin Exp Allergy 2004; 34:1905–1909.
128. Dusmet M, Maurer J, Winton T, et al. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996; 15:948–954.
129. Verleden GM, Buyse B, Delcroix M, et al. Cyclophosphamide rescue therapy for chronic rejection after lung transplantation. J Heart Lung Transplant 1999; 18:1139–1142.
130. Snell GI, Esmore DS, Williams JW. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest 1996; 109: 874–878.
131. Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation 1996; 61:427–430.
132. Date H, Lynch JP, Sundaresan S, et al. The impact of cytolytic therapy on bronchiolitis obliterans syndrome. J Heart Lung Transplant 1998; 17:869–875.
133. Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996; 153:1451–1455.
134. Iacono AT, Capra WB, Shrewsbury B, et al. Long-term follow up of a double-blind, randomized, placebo-controlled trial of cyclosporine inhalation solution (CyIS) in lung transplant recipients. J Heart Lung Transplant 2005; 24(Suppl 2S):S82–S83.
135. Cahill BC, Somerville T, Karwande SW, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22:169–176.
136. Ussetti R, Laporta A, de Pablo A, et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 2003; 35:1974–1977.
137. Ussetti R, Carreno, MC, de Pablo A, et al. Rapamycin and chronic lung rejection. J Heart Lung Transplant 2004; 23:917–918.
138. Verleden GM, Dupont LJ, Vanhaecke J, et al. Effect of azithromycin on bronchiectasis and pulmonary function in a heart lung transplant patient with severe chronic allograft dysfunction. J Heart Lung Transplant 2005; 24(8):1155–1158.
139. Ward C, Camara M, Forrest I, et al. Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients. Thorax 2003; 58: 444–446.
140. Basyigit I, Yildiz F, Yildirim E, et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 2004; 38:1400–1405.
141. Verleden GM, Dupont LJ, Vanaudenaerde BM, et al. Azithromicin reduces airway neutrophilia in patients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2005; 24(Suppl 2S):S59.
142. Chacon RA, Corris PA, Dark JH, et al. Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 2000; 19:263–269.
143. Melville A, Wardle J, Parry G, et al. Comparison of total lymphoid irradiation (TLI) versus tacrolimus for the treatment of obliterative bronchiolitis (OB) in lung transplants. J Heart Lung Transplant 2001; 20(Suppl):S208.
144. Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005; 5:537–543.
145. Slovis BS, Loyd JE, King LE Jr. Photophoresis for chronic rejection of lung allografts. N Engl J Med 1995; 332:962.
146. Salerno CT, Park SJ, Kreykes NS, et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999; 117:1063–1069.
147. Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5:44–47.
148. O’Hagan AR, Stillwell PC, Arroliga A, et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999; 115:1459–1462.
149. Shennib H, Novick R, Mulder D, et al. Is lung retransplantation indicated? Report on four cases. Eur Respir J 1993; 6:354–357.
150. Kotloff RM. Lung retransplantation. All for one or one for all? Chest 2003; 123:1781–1782.
151. Novick R, Stitt LW, Al-Kattan K, et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Ann Thorac Surg 1998; 65:227–234.
152. Brugiere O, Thabut G, Castier Y, et al. Lung retransplantation for bronchiolitis obliterans syndrome. Chest 2003; 123:1832–1837.
153. Schafers HJ, Hausen B, Walters T, et al. Retranspantation of the lung. A single center experience. Eur J Cardiothorac Surg 1995; 9:291–295.
154. Huddleston CB, Mendeloff EN, Cohen AH, et al. Lung retransplantation in children. Ann Thorac Surg 1998; 66:199–204.
155. Novick RJ, Stitt L. Pulmonary retransplantation. Semin Thorac Cardiovasc Surg 1998; 10:227–236.